Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Schizophrenia is a devastating and costly illness. One-third to one-half of people with
schizophrenia do not respond to the most current drugs leaving clozapine as the best
alternative for treatment. However, over 60% of people treated with clozapine continue to
have persistent symptoms and cognitive impairments. Little data is available to support
evidence-based recommendations to guide clinicians in treating these patients. Preliminary
data has suggested that adjunct treatment with minocycline may offer robust symptom
improvement in patients with schizophrenia, including those taking clozapine. Minocycline has
had interesting effects; including suggesting it may have a significant role in treatment of
neurologic and psychiatric disorders. Minocycline is currently available generically; its
side effects are well-described and minimal. The proposed double-blind treatment study seeks
to demonstrate that adjunctive minocycline offers patients superior efficacy for persistent
positive symptoms, cognitive impairments, and/or other components of schizophrenia pathology.
This knowledge could lead to the more effective treatment of patients with schizophrenia. The
research itself may lead to a better understanding of the pathophysiology of positive
symptoms and cognitive impairments, which could contribute to improved treatments in the
future.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore